[go: up one dir, main page]

CU24444B1 - Formulaciones tópicas de heparina - Google Patents

Formulaciones tópicas de heparina

Info

Publication number
CU24444B1
CU24444B1 CU2016000119A CU20160119A CU24444B1 CU 24444 B1 CU24444 B1 CU 24444B1 CU 2016000119 A CU2016000119 A CU 2016000119A CU 20160119 A CU20160119 A CU 20160119A CU 24444 B1 CU24444 B1 CU 24444B1
Authority
CU
Cuba
Prior art keywords
present
formulations
topical
heparin formulations
topical heparin
Prior art date
Application number
CU2016000119A
Other languages
English (en)
Other versions
CU20160119A7 (es
Inventor
A K Patel
K R Patel
M R Patel
Prakash J Shah
Original Assignee
Troikaa Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52684592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24444(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Troikaa Pharmaceuticals Ltd filed Critical Troikaa Pharmaceuticals Ltd
Publication of CU20160119A7 publication Critical patent/CU20160119A7/es
Publication of CU24444B1 publication Critical patent/CU24444B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>La presente invención se relaciona con formulaciones tópicas avanzadas de sales farmacéuticamente aceptables de Heparina que proporcionan penetración transdérmica mejorada. La presente invención proporciona formulaciones líquidas, no pegajosas, claras en las que el fármaco está listo para la absorción y que son adecuadas para administración en la forma de una solución o una pulverización. Las formulaciones tópicas de la presente invención no forman película con escamas o similar al gel sobre la superficie de la piel luego de aplicación tópica.</p>
CU2016000119A 2014-02-10 2015-02-10 Formulaciones tópicas de heparina CU24444B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN475MU2014 2014-02-10
PCT/IB2015/050986 WO2015118512A1 (en) 2014-02-10 2015-02-10 Topical formulations of heparin

Publications (2)

Publication Number Publication Date
CU20160119A7 CU20160119A7 (es) 2016-10-28
CU24444B1 true CU24444B1 (es) 2019-10-04

Family

ID=52684592

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2016000119A CU24444B1 (es) 2014-02-10 2015-02-10 Formulaciones tópicas de heparina

Country Status (25)

Country Link
US (1) US9861655B2 (es)
EP (1) EP3104839B1 (es)
JP (1) JP6275877B2 (es)
KR (1) KR101822133B1 (es)
CN (1) CN106163498A (es)
AP (1) AP2016009350A0 (es)
AR (1) AR099333A1 (es)
AU (1) AU2015213569B2 (es)
CA (1) CA2938388C (es)
CL (1) CL2016001952A1 (es)
CU (1) CU24444B1 (es)
DK (1) DK3104839T3 (es)
DO (1) DOP2016000198A (es)
EA (1) EA032200B1 (es)
EC (1) ECSP16069947A (es)
IL (1) IL246974B (es)
MA (1) MA39304B1 (es)
MX (1) MX357765B (es)
MY (1) MY182620A (es)
NZ (1) NZ722830A (es)
PE (1) PE20161173A1 (es)
PH (1) PH12016501500A1 (es)
TW (1) TWI538697B (es)
UA (1) UA118279C2 (es)
WO (1) WO2015118512A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011239636A1 (en) * 2010-04-13 2012-11-22 Najib Babul Dermal pharmaceutical compositions of 1-Methyl-2',6'-pipecoloxylidide and method of use
CN112546061B (zh) * 2021-02-25 2021-06-11 中南大学湘雅医院 一种肝素类药物组合物、喷鼻剂及其制备方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3323389A1 (de) * 1983-06-29 1985-01-10 B. Braun Melsungen Ag, 3508 Melsungen Auf schleimhaeute des mundes, der nase und/oder des rachens wirkende arzneimittel auf der basis von heparin und tensiden
JPH02207018A (ja) * 1989-02-07 1990-08-16 Kao Corp 皮膚外用剤
ES2180599T3 (es) 1994-09-30 2003-02-16 Mika Pharma Ges Fur Die Entwic Composicion farmaceutica.
IT1275955B1 (it) 1995-03-22 1997-10-24 Dompe Spa Formulazioni farmaceutiche in forma di gel tissotropico
JPH10279466A (ja) * 1997-04-07 1998-10-20 Kose Corp 外用剤
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
BRPI0101486B1 (pt) 2001-04-17 2017-09-19 Cristália Produtos Químicos Farmacêuticos Ltda. Pharmaceutical composition for topic use containing heparin for the treatment of skin or mucosal injuries caused by burns
EP3284470A1 (en) * 2006-11-15 2018-02-21 Arthritis Relief Plus Ltd. Topical formulation comprising comfrey extract
IT1400232B1 (it) * 2010-05-07 2013-05-24 Advance Holdings Ltd Composizione farmaceutica topica comprendente eparina
KR20140024292A (ko) * 2011-04-01 2014-02-28 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 치료제의 국소 전달용 감열성, 점막부착성 또는 표피부착성, 및 침투강화성 제제

Also Published As

Publication number Publication date
AP2016009350A0 (en) 2016-07-31
TWI538697B (zh) 2016-06-21
PE20161173A1 (es) 2016-10-27
MY182620A (en) 2021-01-27
JP2017505344A (ja) 2017-02-16
TW201532631A (zh) 2015-09-01
CL2016001952A1 (es) 2017-03-10
JP6275877B2 (ja) 2018-02-07
MA39304A1 (fr) 2018-01-31
UA118279C2 (uk) 2018-12-26
CN106163498A (zh) 2016-11-23
EP3104839B1 (en) 2019-11-13
MA39304B1 (fr) 2018-12-31
EA032200B1 (ru) 2019-04-30
EA201691596A1 (ru) 2017-01-30
MX357765B (es) 2018-07-23
EP3104839A1 (en) 2016-12-21
DOP2016000198A (es) 2016-10-31
US20170165291A1 (en) 2017-06-15
NZ722830A (en) 2018-01-26
KR101822133B1 (ko) 2018-01-25
AU2015213569B2 (en) 2018-01-04
AR099333A1 (es) 2016-07-13
CU20160119A7 (es) 2016-10-28
MX2016010399A (es) 2017-02-23
ECSP16069947A (es) 2018-06-30
CA2938388A1 (en) 2015-08-13
WO2015118512A1 (en) 2015-08-13
US9861655B2 (en) 2018-01-09
CA2938388C (en) 2018-07-17
AU2015213569A1 (en) 2016-08-18
PH12016501500B1 (en) 2017-02-06
IL246974B (en) 2018-07-31
KR20160117529A (ko) 2016-10-10
PH12016501500A1 (en) 2017-02-06
DK3104839T3 (da) 2020-01-20

Similar Documents

Publication Publication Date Title
EP3622947B8 (en) Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa
DK3273942T3 (da) Mikronåleplaster til indgivelse af en aktiv bestanddel til huden
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX387604B (es) Formulaciones cannabinoides estables.
BR112015020389A8 (pt) compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos
CR20150647A (es) Sistema de liberación transdérmica
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
MX2021010359A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
MX2016000121A (es) Tratamiento de lesiones inflamatorias de rosacea con invermectina.
CR20150360A (es) Sistema de liberación transdérmica
AR096402A1 (es) Medicamento de metformina y dihidroquercetina
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
MX2016013236A (es) Formulacion inmunosupresora.
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
PE20150721A1 (es) Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacion
ECSP16069947A (es) Formulaciones tópicas de heparina
CL2016000397A1 (es) Tratamiento contra el cáncer
CL2018001797A1 (es) Formulación galénica que comprende un fármaco tópico
MX368735B (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
PE20150022A1 (es) Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis
AR130700A2 (es) Composiciones de grapiprant y métodos para su utilización
CO2018005367A2 (es) Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo campo técnico